Value
3.9/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 0.0 |
| P/S | 0.0 |
| Fwd P/E | 5.5 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 23.2x
- ▸PEG: 0.01
ETON · Why this verdict
Why Eton Pharmaceuticals (ETON) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Eton Pharmaceuticals is posting industry-leading revenue growth and strong momentum, but extreme insider selling, a failed asymmetry gate, and a consecutive-miss earnings pattern keep the risk/reward setup unattractive.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The risk/reward setup has failed the engine's asymmetry gate, with a ratio of just 0.23 — 3.5% upside to target against 15.0% downside to stop — consistent with the bear case's thin upside margin. Reward-to-risk math | The asymmetry ratio should remain below the 1.5 gate threshold as long as downside risk this dramatically outweighs modeled upside. | ↑Improving |
| CounterModeled downside of 15% may be an overly conservative stop-loss distance for a small-cap pharma name, and a tighter, more realistic stop could improve the ratio without any change in the underlying thesis. | ||
Eton is flagged as an industry growth leader among peers, with revenue growth of 40% year-over-year driving a growth score of 10 out of 10. Peer-rank breakdown | Revenue growth should stay above 25% YoY and the peer growth rank above 7.0 over the next four quarters. | ↑Improving |
| CounterGrowth-dimension confidence is only 0.33, and the quality profile shows zero ROE and net margin, so top-line growth is not yet converting to bottom-line profitability. | ||
Insider selling has triggered the engine's most severe classification, with insiders selling $7.06 million, 0.69% of market cap, over the past 90 days across 7 sell transactions and zero buys. Warnings | Insider selling severity should de-escalate from extreme as selling activity slows. | ↑Improving |
| CounterLarge insider sales can reflect pre-scheduled selling plans (Rule 10b5-1) tied to personal diversification or tax planning rather than a negative view of the company's prospects. | ||
Momentum is strong but stretched, with an RSI of 83 flagging overbought conditions alongside rising on-balance volume and price above the 200-day moving average, driving a momentum score of 7.5. Momentum breakdown | RSI should cool toward the 50-70 range without a sharp price reversal if the momentum is genuinely durable. | ↓Deteriorating |
| CounterAn RSI this extreme historically precedes short-term pullbacks, and combined with the near-52-week-high bear case flag, a mean-reversion move lower is a real risk. | ||
Eton has missed or only met, never beaten, estimates in its last 4 reported quarters, with 2 outright misses and an average surprise of -17.1%, alongside a leverage penalty from a debt-to-equity ratio of 1.0. Earnings | The company should return to beating estimates in at least 1 of the next 2 reports. | ↑Improving |
| CounterFor an early-commercial-stage specialty pharma company, quarter-to-quarter EPS volatility from R&D and launch spend can produce misses even as the underlying growth story remains intact. | ||
The risk/reward setup has failed the engine's asymmetry gate, with a ratio of just 0.23 — 3.5% upside to target against 15.0% downside to stop — consistent with the bear case's thin upside margin.
↑ImprovingReward-to-risk math
- Expectation
- The asymmetry ratio should remain below the 1.5 gate threshold as long as downside risk this dramatically outweighs modeled upside.
CounterModeled downside of 15% may be an overly conservative stop-loss distance for a small-cap pharma name, and a tighter, more realistic stop could improve the ratio without any change in the underlying thesis.
Eton is flagged as an industry growth leader among peers, with revenue growth of 40% year-over-year driving a growth score of 10 out of 10.
↑ImprovingPeer-rank breakdown
- Expectation
- Revenue growth should stay above 25% YoY and the peer growth rank above 7.0 over the next four quarters.
CounterGrowth-dimension confidence is only 0.33, and the quality profile shows zero ROE and net margin, so top-line growth is not yet converting to bottom-line profitability.
Insider selling has triggered the engine's most severe classification, with insiders selling $7.06 million, 0.69% of market cap, over the past 90 days across 7 sell transactions and zero buys.
↑ImprovingWarnings
- Expectation
- Insider selling severity should de-escalate from extreme as selling activity slows.
CounterLarge insider sales can reflect pre-scheduled selling plans (Rule 10b5-1) tied to personal diversification or tax planning rather than a negative view of the company's prospects.
Momentum is strong but stretched, with an RSI of 83 flagging overbought conditions alongside rising on-balance volume and price above the 200-day moving average, driving a momentum score of 7.5.
↓DeterioratingMomentum breakdown
- Expectation
- RSI should cool toward the 50-70 range without a sharp price reversal if the momentum is genuinely durable.
CounterAn RSI this extreme historically precedes short-term pullbacks, and combined with the near-52-week-high bear case flag, a mean-reversion move lower is a real risk.
Eton has missed or only met, never beaten, estimates in its last 4 reported quarters, with 2 outright misses and an average surprise of -17.1%, alongside a leverage penalty from a debt-to-equity ratio of 1.0.
↑ImprovingEarnings
- Expectation
- The company should return to beating estimates in at least 1 of the next 2 reports.
CounterFor an early-commercial-stage specialty pharma company, quarter-to-quarter EPS volatility from R&D and launch spend can produce misses even as the underlying growth story remains intact.
Per-dimension breakdown
Quality
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 7.9 |
| Gross margin | 8.3 |
| Op margin | 10.0 |
| Net margin | 6.0 |
| Current ratio | 5.6 |
| FCF quality | 4.1 |
| Moat | 8.2 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 36%
- ▸Earnings quality warning: 52% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 99% YoY
Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.0 |
- ▸Overbought (RSI 75)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 4.2 |
| Analyst rating | 7.1 |
| Price target | 6.7 |
- ▸Light analyst coverage (4.0) — signal dampened
Insider
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 6.1 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $12,521,527 (0.731% of mkt cap)
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.1 |
| quality rank | 8.2 |
| growth rank | 9.8 |
- ▸Superior ROE vs peers
- ▸Industry growth leader
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.8 |
| support resistance | 0.2 |
| 52w position | 9.8 |
Risk (lower is worse)
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.6 |
| days to cover | 8.4 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 1.1 |
| beta | 7.8 |
| debt equity | 7.2 |
- ▸High IV: 74%
Catalyst
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.01, quality 7.8/10, growth 10.0/10). | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|L3:NEWS_MOD=-1Passed (5)
- MOMENTUM:7.2>=5.5
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:83d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-0.3=NEGATIVE
- INSIDER:0.73%=EXTREME
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.33
Upside
-4.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $1.7B<$5B
Investment implication
The C-path quality+growth combination triggered the HOLD_IF_HOLDING verdict: quality 7.8 and growth 10.0 both clear their thresholds, with asymmetric R:R of -0.33 supporting the read.
The strongest dimensions are Growth at 10.0, Quality at 7.8, and Momentum at 7.2; the weakest are Technical at 3.6, Value at 3.9, and Insider at 4.3. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -0.33 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Revenue Growth Leader
Trip ifRevenue growth falls below 15% YoY from the current 40%.
- P2Extreme Insider Selling
Trip ifInsider selling as a percentage of market cap falls below 0.2% over the next 90-day window, down from the current 0.69%.
- P3Asymmetry Gate Failure Thin Upside
Trip ifAsymmetry ratio rises above 1.5 from the current 0.23, clearing the engine's gate.
- P4Overbought Momentum
Trip ifRSI falls below 40 alongside a price decline of more than 10% from current levels.
- P5Consecutive Earnings Misses Leverage Penalty
Trip ifCompany beats consensus EPS estimates by more than 10% at 2 consecutive reports.